Diana Hausman Biography and Net Worth

Director of Immuneering

Dr. Hausman has served on our Board of Directors since January 2022. Dr. Hausman currently serves as a part-time consulting Chief Medical Officer for Reverb Therapeutics, a pre-clinical stage biotechnology company. Previously, she was Chief Medical Officer at Zentalis Pharmaceuticals, Inc. ("Zentalis"), a position she served from January 2024 to August 2024, having previously served as a member of the Board of Directors at Zentalis from May 2023 until January 2024. Prior to Zentalis, Dr. Hausman served as the Chief Medical Officer of Link Immunotherapeutics from March 2022 to October 2023, and from June 2021 to March 2022 served as the Chief Medical Officer of Lengo Therapeutics ("Lengo"), a wholly-owned subsidiary of Blueprint Medicines Corporation. Prior to Lengo, Dr. Hausman served as Chief Medical Officer for Zymeworks Inc. from June 2016 to May 2021, and as Chief Medical Officer for Oncothyreon Inc. from 2009 to 2016. She also held positions of increasing responsibility at ZymoGenetics Inc., Berlex Inc., and Immunex Corporation, working across multiple indications, including oncology, hematology, hepatitis C and autoimmune disease. Dr. Hausman received her A.B. in biology from Princeton University, her M.D. from the University of Pennsylvania, and her internal medicine and specialty training in hematology and medical oncology at the University of Washington, Seattle.

What is Diana Hausman's net worth?: The estimated net worth of Diana Hausman is at least $16.18 thousand as of July 2nd, 2025. Dr. Hausman owns 3,000 shares of Immuneering stock worth more than $16,176 as of May 4th. This net worth estimate does not reflect any other investments that Dr. Hausman may own. Learn More about Diana Hausman's net worth.
How do I contact Diana Hausman?: The corporate mailing address for Dr. Hausman and other Immuneering executives is , , . Immuneering can also be reached via phone at 617-500-8080 and via email at [email protected]. Learn More on Diana Hausman's contact information.
Has Diana Hausman been buying or selling shares of Immuneering?: Diana Hausman has not been actively trading shares of Immuneering during the last quarter. Most recently, on Wednesday, July 2nd, Diana Hausman bought 3,000 shares of Immuneering stock. The stock was acquired at an average cost of $3.62 per share, with a total value of $10,860.00. Following the completion of the transaction, the director now directly owns 3,000 shares of the company's stock, valued at $10,860. Learn More on Diana Hausman's trading history.
Who are Immuneering's active insiders?: Immuneering's insider roster includes Diana Hausman (Director), and Benjamin Zeskind (CEO). Learn More on Immuneering's active insiders.
Are insiders buying or selling shares of Immuneering?: In the last year, Immuneering insiders bought shares 21 times. They purchased a total of 200,126 shares worth more than $712,543.52. The most recent insider tranaction occured on January, 16th when insider Harold Eugene Brakewood bought 5,250 shares worth more than $24,990.00. Insiders at Immuneering own 22.9% of the company. Learn More about insider trades at Immuneering.
Information on this page was last updated on 1/16/2026.

Diana Hausman Insider Trading History at Immuneering

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/2/2025	Buy	2,500	$3.60	$9,000.00	2,500
7/2/2025	Buy	3,000	$3.62	$10,860.00	3,000

Diana Hausman Buying and Selling Activity at Immuneering

Immuneering Company Overview

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Today's Range

Now: $5.46

$5.36

$5.53

50 Day Range

MA: $5.31

$4.78

$6.13

2 Week Range

Now: $5.46

$1.10

$10.08

Volume

264,892 shs

Average Volume

1,397,065 shs

Market Capitalization

$353.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.37